Denali Therapeutics/$DNLI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Denali Therapeutics
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.
Ticker
$DNLI
Sector
Primary listing
Employees
486
Headquarters
Website
DNLI Metrics
BasicAdvanced
$2.4B
-
-$2.81
1.36
-
Price and volume
Market cap
$2.4B
Beta
1.36
52-week high
$31.56
52-week low
$10.57
Average daily volume
2.2M
Financial strength
Current ratio
10.265
Quick ratio
9.872
Long term debt to equity
3.669
Total debt to equity
4.533
Interest coverage (TTM)
-254.08%
Profitability
EBITDA (TTM)
-529.42
Effective tax rate (TTM)
-0.01%
Management effectiveness
Return on assets (TTM)
-24.99%
Return on equity (TTM)
-39.69%
Valuation
Price to book
2.29
Price to tangible book (TTM)
2.29
Price to free cash flow (TTM)
-7.496
Free cash flow yield (TTM)
-13.34%
Free cash flow per share (TTM)
-2.157
Growth
Earnings per share change (TTM)
-0.60%
3-year earnings per share growth (CAGR)
6.59%
What the Analysts think about DNLI
Analyst ratings (Buy, Hold, Sell) for Denali Therapeutics stock.
Bulls say / Bears say
FDA has accepted Denali’s BLA for tividenofusp alfa under Priority Review with a PDUFA target action date of January 5, 2026, positioning its first BBB-penetrant enzyme replacement therapy for potential accelerated approval. (Nasdaq)
Denali initiated rolling BLA submission for tividenofusp alfa in early May 2025 and achieved FDA alignment on surrogate endpoint use via the START program for DNL126, underscoring robust regulatory engagement and momentum. (Nasdaq)
The company ended Q2 2025 with $977.4 million in cash, equivalents and marketable securities, providing over two years of operational runway amid intensified R&D activities. (GlobeNewswire)
Net loss widened to $124.1 million in Q2 2025 from $99.0 million a year earlier as R&D and G&A expenses surged for manufacturing build-out and commercial launch preparations, increasing cash burn. (GlobeNewswire)
Denali’s DNL343 eIF2B activator for ALS failed to meet the primary endpoint in the HEALEY Phase 2/3 platform trial, and subsequent biomarker analyses showed no significant neurofilament light reduction, casting doubt on program viability. (GlobeNewswire)
In February 2025, Denali and Sanofi terminated the CNS RIPK1 inhibitor collaboration (SAR443820/DNL788), and Takeda ended the ATV:TREM2 program in April 2025, eliminating potential future milestone and royalty streams. (SEC Filing)
Data summarised monthly by Lightyear AI. Last updated on 9 Oct 2025.
DNLI Financial Performance
Revenues and expenses
DNLI Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Denali Therapeutics stock?
Denali Therapeutics (DNLI) has a market cap of $2.4B as of October 11, 2025.
What is the P/E ratio for Denali Therapeutics stock?
The price to earnings (P/E) ratio for Denali Therapeutics (DNLI) stock is 0 as of October 11, 2025.
Does Denali Therapeutics stock pay dividends?
No, Denali Therapeutics (DNLI) stock does not pay dividends to its shareholders as of October 11, 2025.
When is the next Denali Therapeutics dividend payment date?
Denali Therapeutics (DNLI) stock does not pay dividends to its shareholders.
What is the beta indicator for Denali Therapeutics?
Denali Therapeutics (DNLI) has a beta rating of 1.36. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.